Default company panoramic image
Logo

Thermalin Diabetes, LLC

New insulins for recognized needs in $17B market, as leading insulins come off patent. $10M additional on B leads to initial out-licensing in 2015.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Newton, MA, USA
  • Currency USD
  • Founded April 2009
  • Employees 15
  • Incorporation Type LLC
  • Website thermalin.com

Company Summary

Thermalin is developing next-generation insulins to fill gaps in a rapidly growing $17B market. Our new molecules include ultra-concentrated, rapid-acting ($3B addressable), ultra-rapid-acting/fast offset meal-time and pump ($4B), and ultra-heat stable, long- and rapid-acting ($1.8B+) insulins. Existing marketed insulin analogs go off-patent in 2014-16; in preparation, at least 5 major pharmas are actively shopping for superior insulins.

Team

  • Default avatar
    Michael Weiss
    Chief Scientific Officer

    Professor and Chairman of Biochemistry at CWRU School of Medicine, Mike has > 150 publications, including four on his insulin analogs named “Paper of the Week” by the Journal of Biological Chemistry. Mike just completed a 5 year term as chair of the NIDDK’s Board of Scientific Councilors. He earned his A.B., summa cum laude in Physics in 1978, his M.D., summa cum laude, in 1985, and a Ph.D. in biophysics in 1986, all from Harvard University.

  • Default avatar
    Bruce Frank
    VP Insulin Development

    Bruce was co-inventor of Humalog and retired from Eli Lilly after 34-years in which he held several senior management positions in insulin discovery, development, manufacturing, and regulatory affairs. He received his Ph.D. in Physical Biochemistry from Northwestern and did his post-doc at Berkley.

  • Photo
    Chief Executive Officer

    Rick is a serial entrepreneur who has successfully launched and financed multiple life science and other organizations around important new technologies in complex markets. A former McKinsey consultant, Rick received a JD-MBA from Harvard Business and Law Schools in 1984 and is a graduate of Harvard College.

  • Default avatar
    Jeffrey Elton
    Director

    Accenture Life Sciences; former COO, Novartis Institutes for BioMedical Research; Former Director, McKinsey & Company

  • Default avatar
    John Brooks
    Chairman

    President & CEO, Joslin Diabetes Center; Founder, Prism Ventures

  • Default avatar
    Thomas Hattier
    VP of R & D

    Thom is an accomplished researcher, who has driven development efforts in the biotech and biopharma sectors, including at Myriad Genetics, AmpliCon, and Cellular Technology. Thom earned a BA at Connecticut College; an MS in biochemistry, PhD in pathology, and completed post-doctoral work in molecular genetics, all at Case Western Reserve University.

Advisors

  • Default avatar
    Jameson & Co, and Wolf & Company
    Accountant
    Unconfirmed
    Default avatar
    Michael Barron
    Attorney
    Unconfirmed

Previous Investors

  • Default avatar
    Massachusetts Medical Angels
    Unconfirmed
    Default avatar
    JumpStart Ventures
    Unconfirmed